Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study

LUND, SE / ACCESS Newswire / June 10, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and therefore at risk of developing lung cancer. The study is an investigator-led initiative in collaboration with Drs. Robert Samstein, Thomas Marron and Miriam Merad at Mount Sinai Tisch Cancer Center, New York.

Raccontata damorningstar.com